Aerosurf inhaled surfactant developer Windtree Therapeutics has announced the completion of a $26.4 million private placement of common stock and warrants. Net proceeds were approximately $23 million.
Windtree is developing several inhaled drugs delivered via the company’s proprietary Aerosol Delivery System (ADS). In addition to Aerosurf inhaled KL4 surfactant, which is in Phase 2 development for the treatment of respiratory distress syndrome (RDS) in premature infants, the company is developing inhaled liquid cisplatin (ILC) for the treatment of lung cancer in partnership with Eleison Pharmaceuticals. Windtree has said in the past that it might consider developing a formulation of ILC that includes its KL4 surfactant.
Read the Windtree Therapeutics press release.
